Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to integrate the work of (a) NICE, (b) NHS England, (c) health industry representatives and (d) the UK Medicines and Healthcare products Regulatory Agency on adopting new dementia treatments.

The Government wants patients to benefit from rapid access to safe and effective new medicines in a way that represents value to the taxpayer. The Medicines and Health products Regulatory Agency (MHRA) reviews medicinal products for quality, safety and efficacy and if satisfied, will provide an appropriate marketing authorisation or licence for the United Kingdom, detailing the safe use and target population. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. Wherever possible the NICE aims to publish recommendations on new medicines around the time of licensing.

With the consent of the marketing authorisation holders, the NICE and the MHRA have piloted enhanced information sharing arrangements for the new disease modifying treatments for dementia. The pilots have enabled the organisations to fully align their processes and announce marketing authorisation decisions and draft recommendations on the same day for the first two licensed disease modifying treatments. The MHRA, the NICE, NHS England, and counterparts in the other UK nations are working closely together to ensure that the NHS is prepared for the rollout of any licensed and NICE-recommended new dementia treatments.